Detection of BRAF Gene Mutation in Preoperative Diagnostic of Thyroid Gland Cancer

Cover Page

Abstract


Purpose: To assess the utility of BRAFV600E mutation detection in preoperative thyroid cancer diagnostic. Material and methods: We studied 46 aspirates taken by FNA from patients with thyroid gland nodes. Thyroid tissue aspirates DNA was extracted by sorbent method. BRAF gene mutation was analyzed with primers specific for wild and mutant gen type by RT-PCR. Results: All patients were divided into three groups by cytological conclusions: colloid nodules (9), PTC (19), and suspicious for malignancy (18). In the group of patients with PTC all diagnoses were confirmed by histology, and BRAF gene mutation was detected in 15 (79%) FNAB specimens. In the group with suspicious cytological diagnosis only one patient had follicular cancer by histology and positive BRAF mutation. There were detected no BRAF mutation in 16 patients with histologically proven follicular adenoma, in 9 patients with colloid nodular goiter and in one patient with follicular cancer. Thereby, we received the following criteria valuers of method’s reliability: sensitivity – 76%, specificity – 100%, diagnostic accuracy – 89%. Conclusions: Detection of the BRAFV600E mutation may be a useful adjunct marker for preoperative diagnostic of thyroid gland cancer.

About the authors

Email: medici@yandex.ru

References

  1. Валдина Е.А. Заболевания щитовидной железы: Руководство. 3-е изд. СПб.: Питер, 2006.
  2. Гринева Е.Н. Узловые образования щитовидной железы. Диагностика и врачебная тактика // Пробл. эндокринол. 2003. Т. 49. №6. C. 59–62.
  3. Пачес А.И., Пропп Р.М. Рак щитовидной железы. М., 1995.
  4. Томашевский И.О. Рентгенофлюоресцентный метод в дифференциальной диагностике заболеваний щитовидной железы // Пробл. эндокринол. 1997. Т. 43. № 3. C. 38–42.
  5. Brzezianska E., Pastuszak-Lewandoska D., Wojciechowska K. et al. Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population // Neuroendocrinol. Let. 2007. V. 28(4). P. 351–359.
  6. Burch H.B Evaluation and management of the solid thyroid nodule // Endocrinol. Metab. Clin. N. Am. 1995. V. 24. N 4. P. 663–698.
  7. Cibas E.S., Ducatmann B.S. Cytology / Diagnos principles and clinical correlates. A division of Harcourt Brace Company. Philadelphia – London – Toronto – Montreal – Sydney – Tokyo: WB Sunders company, 1996. P. 217–242.
  8. Viola D., Romei Cr., Biagini A. et al. Prognostic significance of BRAF mutation in patients affected by papillary thyroid carcinoma with a follow up of 20 years // J. Clin. Endocrinol. 2007. V. 75(4). P. 325–324.
  9. Fugazzola L., Puxeddu E., Avenia N. et al. Correlation between B-RAFV600E mutation and clinic-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italy study and review of the literature // Endocrin. Relat. Cancer. 2006. V. 13(2). P. 455–464.
  10. Gharib H. Fine-needle aspiration biopsy of thyroid nodules: advantages, limitations, and affect // Meyo Clin. Proc. 1994. V. 69. P. 44–49.
  11. Kebebew E., Weng J., Bauer J. et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer // Ann. Surg. 2007. V. 246(3). P. 466–470.
  12. Kimura E.T., Nikiforova M.N., Zhu Z. et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitu+ tive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma // Canc. Res. 2003. V. 63. P. 1454–1457.
  13. Chung K.9W., Yang S.K. et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule cytopathology diagnosis, especially in BRAFV600E mutation-prevalent area //. 2006. V. 65(5). P. 660–666.
  14. Lee J.H., Lee E.S., Kim Y.S. Clinicopathologic significance of BRAF V600V mutation in papillary carcinomas of the thyroid: a meta+analysis // Am. Canc. Soc. 2007. V. 10. P. 38–46.
  15. Rowe L.R., Bentz Br.G., Bentz J.S. Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules // Cyto J. 2006. V. 3. P. 10–15.
  16. Linn S. A new conceptual approach to teaching the interpretation of clinical tests // J. Sta. Educat. 2004. V. 12. N 3. P. 11–18.
  17. Xing M., Tufano R.P., Tufaro A.P. et al. Detection of BRAF Mutation on Fine Needle Aspiration Biopsy Specimens: A New Diagnostic Tool for Papillary Thyroid Cancer // J. Clin. Endocrinol. Metab. 2004. V. 89(6). P. 2867–2872.
  18. Namba H., Nakashima M., Hayashi T. et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers // J. Clin. Endocrinol. Metab. 2003. V. 88. P. 4393–4397.
  19. Tan G.H., Gharib H. Thyroid incendentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging // Ann. Intern. Med. 1997. V. 126. N 3 P. 226–231.
  20. Trovisco V., Soares P., Preto A. et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness // 2005. V. 446(6). P. 589–595.
  21. Ugolini Cl., Giannini R., Lupi Cr. Presence of BRAF V600E in very early stages of papillary thyroid carcinoma // Thyroid. 2007. V. 17. N 5. P. 381–388.
  22. Xu X., Quiros R.M., Gattuso P. et al. High Prevalence of BRAF Gene Mutation in Papillary Thyroid Carcinomas and Thyroid Tumor Cell Lines // Cancer research. 2003. V. 63. P. 4456–4561.

Statistics

Views

Abstract - 991

PDF (Russian) - 1031

Cited-By


PlumX

Dimensions


Copyright (c) 2009 ., ., ., ., ., ., ., ., .

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies